NEJM
New England Journal of Medicine
NEJM
Clinician
NEJM
Evidence
NEJM
AI
NEJM
Catalyst
NEJM
Voices
Loading...
NEJM Research Summary
Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
New England Journal of Medicine
Mar 11
1 min read
New England Journal of Medicine
March 11
1 min read
New England Journal of Medicine
March 11
1 min read
Related Content
Original Article
Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Topics
Hematology/Oncology
Hemostasis and Thrombosis
Clinical Medicine
Ambulatory Medicine